How Quitting Smoking Can Quickly Lower Risk Of A-Fib
Smokers who make the decision to quit will experience immediate health benefits, including a rapid reduction in their risk of atrial fibrillation (A-Fib), according to new research published in JACC: Clinical Electrophysiology. The study, conducted by Dr. Gregory Marcus, a cardiologist at the University of California, San Francisco, offers compelling evidence for smokers to quit, showing that it’s never too late to avoid the damaging effects of smoking on heart health.
Dr. Marcus, the senior author of the study, emphasized that A-Fib can be prevented even in individuals who have smoked for years. "The findings provide a compelling new reason to show current smokers that it’s not too late to quit, and that having smoked in the past doesn’t mean you’re ‘destined’ to develop A-Fib," Marcus explained. "Even for the current and longtime smoker, A-Fib can still be avoided."
"There’s strong evidence that smoking increases the risk of A-Fib," Marcus said. "But the benefits of quitting smoking have been less certain." With this in mind, his team sought to determine whether quitting could significantly lower a person’s risk of developing A-Fib, or if the risk would remain the same.
The research team analyzed data from over 146,700 current and former smokers, tracking their smoking habits and health over a 12-year period using data from the UK Biobank database. The results were promising: former smokers had a 13% lower risk of developing A-Fib compared to current smokers, while those who quit during the study saw an 18% reduction in their risk.
"This is likely a testament to the potency of reducing atrial fibrillation risk pretty shortly after quitting," Marcus said in a statement from the American College of Cardiology.
The findings highlight the importance of quitting smoking, not only for general health but specifically for reducing the risk of serious heart conditions like A-Fib.
Quitting smoking is one of the most effective ways to lower the risk of A-Fib and improve overall heart health. While it can be challenging, the benefits of quitting are clear and immediate. Here are some tips to help you quit smoking successfully:
1. Choose a specific date to quit smoking and stick to it. Prepare yourself mentally and physically for this change.
2. Reach out to family, friends, or a support group to help keep you accountable. Sharing your goals with others can provide encouragement.
3. Options like nicotine patches, gum, or lozenges can help ease withdrawal symptoms and reduce cravings.
4. Identify situations that make you want to smoke, such as stress or social gatherings, and find healthy ways to cope with them.
5. Regular exercise can help distract you from cravings and improve your mood during the quitting process.
6. Drinking water can help flush nicotine out of your system faster, reducing cravings.
7. Activities like yoga, meditation, or deep breathing exercises can help manage stress, a common trigger for smoking.
Quitting smoking offers immediate and significant benefits, particularly in reducing the risk of atrial fibrillation. The latest research provides smokers with more motivation to quit, showing that it's never too late to take control of their heart health.
Credit: iStock
Nearly all countries are overusing antibiotics—particularly those meant for specific conditions—fueling the global threat of antimicrobial resistance (AMR), according to a study published in The Lancet Public Health.
The study, led by researchers from the Universities of London and Oxford, found that 99% of countries overuse "Watch" antibiotics, while 60% continue to use antibiotics that the World Health Organization (WHO) advises should no longer be prescribed.
"Our findings show the world faces a double challenge – while some antibiotics are being overused, millions of people may still lack access to the medicines they need to treat their infections," said Aislinn Cook, lead author and Senior Research Fellow in Infectious Diseases Epidemiology at City St George's, University of London.
Also read: Shigella Driving Antibiotic-Resistant Bacterial Diarrhea Among Gay Men in UK, Lancet Study Finds
The WHO groups antibiotics into three categories under its AWaRe framework:
In 2024, UN member states agreed that at least 70% of global antibiotic use should come from the Access group by 2030.
Researchers estimated that around 43 billion antibiotic courses were needed globally in 2019—roughly one course per person per year to treat bacterial infections. About 77% of these should have been Access antibiotics, suggesting the UN's 70% target is achievable.
However, analysis of antibiotic use across 67 countries revealed widespread inappropriate prescribing:
Read More: 645 Million People Went Hungry in 2025; Middle East Conflict Driving Food Prices: UN
The study also highlighted major disparities in antibiotic access. Researchers noted that low- and middle-income countries, which bear a higher burden of infectious diseases and antimicrobial resistance, often need greater access to specialized Watch and Reserve antibiotics.
Yet these medicines are used more frequently in high-income countries, pointing to unequal access rather than clinical need.
A separate study found that antibiotic-resistant bacteria are increasingly leaving children vulnerable to common infections.
The research, led by the Murdoch Children's Research Institute (MCRI) and covering 82 countries, found that antibiotic resistance increased across every region between 2004 and 2022, making many life-saving drugs used to treat common childhood infections less effective.
Published in the Journal of the American Medical Association, the study found that babies, children in intensive care, and those living in countries with limited healthcare resources are the most affected.
Researchers called for stronger national policies to curb unnecessary antibiotic prescribing while ensuring patients who genuinely need specialized antibiotics can access them.
They stressed that improving access will require coordinated action at both local and national levels. This includes:
Credit: AI
Do partners and spouses of those suffering from dementia face a higher risk of the disease themselves? A nationwide study involving more than 955,000 married adults has found that people whose spouse develops dementia may face a significantly higher risk of developing the condition themselves.
The study, published in JAMA Network Open, adds to growing evidence that dementia risk may not be influenced by genetics and lifestyle alone, but also by the shared environments, lifestyles and experiences couples build over decades.
Also read: Neurological Disorders Emerging As India's Next Major Public Health Challenge, Say Experts
Researchers analyzed health data from 955,105 married individuals in Taiwan to examine whether being married to someone with dementia influences a person's own likelihood of developing the disease.
The researchers found that spouses of people with dementia had a substantially higher risk of developing dementia themselves compared with those whose partners did not have the condition.
Among women, having a spouse with dementia was associated with a 74% higher risk of developing dementia (hazard ratio [HR] 1.74). Among men, the risk was 69% higher (HR 1.69).
The association remained consistent across different forms of dementia, including:
The association appeared to be weaker among couples with higher household incomes or more children, suggesting that social and family support may help reduce some of the caregiving burden.
Also read: Excessive TV Watching In Midlife May Shrink Brain Areas Essential For Memory, Study Finds
The findings do not suggest that dementia spreads from one spouse to another. Instead, researchers believe the increased risk is likely driven by several shared factors that accumulate over years of living together. These include:
Because married couples often share many aspects of daily life, they may also share health risks that influence cognitive ageing.
Also read: Cannabis-Based Treatment Shows Promise In Easing Agitation In Dementia: New Clinical Trial
When one partner develops dementia, the other often becomes the primary caregiver. Caregiving can involve years of emotional stress, disrupted sleep, depression, social isolation and physical exhaustion.
Older research has shown that chronic stress may negatively affect brain health through hormonal, inflammatory and vascular pathways, potentially contributing to cognitive decline.
The authors wrote, "The association was evident on relative and absolute scales and varied by family and socioeconomic context."
They added that future studies should directly measure caregiving intensity, lifestyle factors and other shared pathways to better understand why spouses appear to face an elevated dementia risk.
The findings suggest that healthcare providers should pay attention not only to people diagnosed with dementia but also to their spouses. Experts say spouses may benefit from:
Early recognition of cognitive changes may allow interventions that help delay progression and improve quality of life.
According to recent studies, various factors could influence your risk of developing dementia. Researchers from the University of Southern California studied health data from more than 214,000 adults across 21 countries.
They found that while many well-known dementia risk factors are universal, their impact can vary significantly depending on a person's country.
Previous research has estimated that nearly 45% of dementia cases could potentially be delayed or prevented by addressing modifiable risk factors, including controlling blood pressure, managing diabetes, staying physically active, treating hearing loss, avoiding smoking, and maintaining social life.
Credit: AI
GLP-1 drugs widely used to manage and treat obesity and type 2 diabetes may also help people stay healthier at work. A new study finding that the medications were associated with a 17.3% reduction in absence due to sickness among employed adults.
The study, conducted by researchers from the University of Copenhagen, the University of Chicago, Duke University, and the ROCKWOOL Foundation, analyzed nationwide Danish health and employment records to examine whether GLP-1 treatment affects the conditions of labour market.
Researchers found that people who started GLP-1 therapy experienced significantly fewer episodes of medically certified sick leave lasting longer than 30 days compared with similar patients who began treatment later.
"We find that GLP-1 treatment reduces long-term sickness absence by 17.3% over four years," the researchers wrote in the working paper.
The reduction became more pronounced over time, increasing from around 0.8 percentage points in the first two years after treatment began to 1.1 percentage points during years three and four.
Also read: Can Ozempic-Like GLP-1 Drugs Slow Aging, Boost Longevity?
GLP-1 receptor agonists, including Ozempic and Wegovy, have become best known for helping people lose weight. However, researchers say their benefits may extend well beyond weight loss. The study also found that patients receiving GLP-1 therapy had:
Together, these statistics translated into estimated annual savings equivalent to 1.3% to 1.5% of an employed person's yearly income through fewer prolonged absences from work.
"Our findings suggest meaningful fiscal spillovers from GLP-1 treatment through reduced sickness absence," the authors said.
However, the researchers found no significant evidence that the medications increased overall employment, labor-force participation, or earnings during the four-year follow-up period.
Also read: Novo Nordisk Launches Awiqli In India: All About The World's First Once-Weekly Insulin
The researchers believe the medications likely improve people's overall health enough to reduce serious illnesses that keep them away from work.
GLP-1 drugs work by mimicking a hormone called glucagon-like peptide-1, which helps regulate appetite, blood sugar and digestion. They are known to:
These health improvements may translate into fewer hospital visits and fewer prolonged medical absences.
The researchers cautioned that the findings should not be interpreted as evidence that GLP-1 drugs automatically improve workplace productivity.
The study was based on Danish national data, where healthcare access and paid sick-leave policies differ from those in countries such as the United States and India.
In addition, the study focused on patients prescribed GLP-1 medications for medical reasons, including obesity and type 2 diabetes, rather than people using the drugs primarily for cosmetic weight loss.
The findings add to a growing body of evidence suggesting GLP-1 drugs may offer benefits beyond managing diabetes and obesity. Previous research has linked these medications to lower risks of heart disease, kidney disease, obstructive sleep apnea, and certain liver conditions.
If confirmed across different countries, the latest findings suggest that the drugs could also provide broader economic benefits by reducing long-term sickness absence and easing the burden on healthcare systems.
© 2024 Bennett, Coleman & Company Limited